2024-11-06 - Analysis Report
## Merck & Co. Inc. (MRK) Stock Analysis Report 

This report provides a comprehensive analysis of Merck & Co. Inc. (MRK) stock, covering key metrics, recent performance, and insights from various sources.

**1. Performance Comparison:**

Merck & Co. Inc. (MRK) is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products. 

* **Cumulative Return:** MRK has delivered a cumulative return of 57.67%, while the S&P 500 (VOO) has yielded 134.06% over the same period. This indicates MRK's performance has lagged behind the broader market.
* **Relative Lag:** The current relative lag of MRK against VOO stands at -76.39%. This means MRK is significantly underperforming the market, placing it at the 9.51 percentile of its historical range.
* **Alpha & Beta Analysis:** The alpha and beta values across different periods reveal mixed performance. MRK exhibits lower beta values in recent years, suggesting it is less volatile compared to the overall market. However, the fluctuating alpha values highlight the inconsistency in its outperformance compared to the benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $101.65
* **5-day Moving Average:** $102.51
* **20-day Moving Average:** $106.46
* **60-day Moving Average:** $112.22

The recent price movement suggests a downtrend, as the closing price is below all three moving averages. 

**3. Technical Indicators:**

* **RSI:** 13.67 - This extremely low RSI indicates the stock is deeply oversold.
* **PPO:** -0.3 - The negative PPO suggests a bearish momentum.
* **Relative Divergence:** -10.76 -  The recent decline in relative divergence signals a short-term bearish trend.
* **Expected Return:** 0.0% -  The expected return is 0%, suggesting a potential for long-term growth in line with the S&P 500.

**4. Recent Earnings Performance:**

| Date        | EPS      | Revenue      |
|-------------|----------|--------------|
| 2024-08-05 | 2.15     | $16.11 B$    |
| 2024-05-03 | 1.88     | $15.78 B$    |
| 2023-11-03 | 1.87     | $15.96 B$    |
| 2023-08-07 | -2.35    | $15.04 B$    |
| 2024-08-05 | -2.35    | $15.04 B$    |

The most recent earnings (2024-08-05) show a positive EPS of 2.15 and revenue of $16.11 billion. This beat analyst expectations, indicating continued growth in the pharmaceutical sector. 

**5. Financial Data:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2024-06-30 | $16.11B | 76.76%       |
| 2024-03-31 | $15.78B | 77.56%       |
| 2023-12-31 | $14.63B | 73.26%       |
| 2023-09-30 | $15.96B | 73.29%       |
| 2023-06-30 | $15.04B | 73.24%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2024-06-30 | $43.58B | 12.52%  |
| 2024-03-31 | $40.36B | 11.80%  |
| 2023-12-31 | $37.58B | -3.26%  |
| 2023-09-30 | $41.25B | 11.50%  |
| 2023-06-30 | $38.69B | -15.44% |

Merck demonstrates strong profitability, with consistently high profit margins. The recent earnings reports indicate a healthy revenue growth. However, the ROE fluctuates and indicates a mix of periods of positive and negative returns.

**6. News and Recent Issues:**

* Recent earnings reports highlight a positive growth in the pharmaceutical sector, with MRK exceeding analyst expectations in the recent quarter.
* Recent market outlook: FINBOLD reports that MRK has a “buy” rating with a potential upside of 27.99%.
* Analyst opinions: Most analysts maintain a positive outlook for MRK, citing its strong pipeline and diversified portfolio of products.

**7. Overall Analysis:**

MRK's recent performance has lagged behind the broader market, but its strong financial position and positive earnings indicate potential for future growth. The technical indicators suggest the stock is oversold and could be ripe for a bounce. Investors looking for long-term growth with a focus on pharmaceutical companies should consider MRK, as its strong fundamentals offer potential for outperformance.

**8.  Investment Recommendation:**

MRK presents an attractive opportunity for long-term investors, with its solid financial foundation and growth potential in the pharmaceutical sector. While its recent performance has been underwhelming, the technical indicators suggest a possible rebound.

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. Please consult with a financial professional for personalized advice tailored to your specific needs. 
